The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 04, 2025

Filed:

Apr. 11, 2019
Applicant:

Foundry Therapeutics, Inc., Menlo Park, CA (US);

Inventors:

Karun D. Naga, Los Altos, CA (US);

Hanson S. Gifford, Iii, Woodside, CA (US);

Stephen W. Boyd, San Francisco, CA (US);

Patrick H. Ruane, El Dorado Hills, CA (US);

Jackie Joe Hancock, Berkeley, CA (US);

Michael Feldstein, San Francisco, CA (US);

Koon Kiat Teu, Singapore, SG;

Honglei Wang, Singapore, SG;

Jingnan Luo, Singapore, SG;

Daniel Boon Lim Seet, Singapore, SG;

Wei Li Lee, Singapore, SG;

Nassireddin Mokarram-Dorri, Campbell, CA (US);

Assignee:

Foundry Therapeutics, Inc., Menlo Park, CA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 9/00 (2006.01); A61K 9/70 (2006.01); A61K 31/445 (2006.01); A61K 47/26 (2006.01); A61K 47/34 (2017.01); A61P 23/02 (2006.01);
U.S. Cl.
CPC ...
A61K 9/0024 (2013.01); A61K 9/7007 (2013.01); A61K 31/445 (2013.01); A61K 47/26 (2013.01); A61K 47/34 (2013.01); A61P 23/02 (2018.01);
Abstract

The present technology relates to depot assemblies for the controlled, sustained release of a therapeutic agent. The assembly can include a depot having a therapeutic region comprising a therapeutic agent, and a control region comprising a bioresorbable polymer and a releasing agent mixed with the polymer. The releasing agent may be configured to dissolve when the depot is placed in vivo to form diffusion openings in the control region. The depot may be configured to be implanted at a treatment site in vivo and, while implanted, release the therapeutic agent at the treatment site for no less than 3 days.


Find Patent Forward Citations

Loading…